Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [16][17] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [17][19] - The company finished the year with approximately $561 million in cash and equivalents, and with roughly $140 million in available committed government funding, totaling around $700 million in available liquidity [19][20] Business Line Data and Key Metrics Changes - The pipeline expanded from two preclinical programs at the beginning of the year to four clinical programs by year-end, with ABCL635 advancing to a randomized, double-blind, phase II study [7][11] - The company initiated work on one additional partner-initiated program, bringing the cumulative total to 104 programs with downstream participation [12][14] Market Data and Key Metrics Changes - The company anticipates two clinical readouts in 2026 and aims to have five clinical stage programs across various large market indications by mid-2027 [10][11] - The focus on internal programs is expected to lead to lower research fee revenues as the company prioritizes its proprietary pipeline [16] Company Strategy and Development Direction - The company aims to transition into a vertically integrated clinical-stage biotech, focusing on building its pipeline rather than its platform [5][6] - Key priorities for 2026 include delivering top-line readouts for ABCL635 phase II and ABCL575 phase I studies, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the integrated platform and competitive advantage in antibody discovery and development, with a focus on executing the strategy with available capital [6][12] - The company acknowledges the uncertainty in drug development but remains committed to advancing its pipeline, particularly with ABCL635, which has the potential for blockbuster status [9][10] Other Important Information - The company has made substantial investments in property, plant, and equipment to establish clinical manufacturing capabilities, which are now substantially complete [18] - The clinical manufacturing facility is expected to improve supply chain control, flexibility, and protect intellectual property [18] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes OX40 ligand has a broad effect on the immune system and is considering combination strategies with external parties [24][25] Question: Oncology-based VMS studies - Management sees opportunities in breast and prostate cancer patients experiencing severe hot flashes and believes safety and convenience will differentiate their product [29][30] Question: Target engagement data for ABCL635 - The phase I safety and target engagement data will be released alongside the phase II data in Q3 [34][35] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple clinical programs and is committed to ensuring adequate operational capacity [47][48] Question: Decision factors for ABCL575 development - The decision will largely depend on external factors, including partnership opportunities and the competitive landscape [49][50]